Optibiotix Health Share Discussion Threads

[elrico] 04/12/2016 22:40

Glancy - I guess from the vote you are not alone in wanting answers to the 3 questions. The header is the 1st post set up with useful links by the author or administrator, if you will of this thread. It is whom is SOH? Stephen O'Hara, He is the CEO founder and founder of the company. What is missing from the header - an email reply from SOH I received offering him what I understood about the science, IP's and various strains and how I thought their be cross commercial potential. At the time, this had not been discussed and I thought we were missing out on a very important topic for the future, thus greater potential than perhaps some of us realised. SOH sent me a detailed reply confirming what I hoped would be the case. Unfortunately, this has now been removed from the header. However, if you or anyone wants a copy I still have it. PM and Ill send it. That said, and don't take this the wrong way...I suspect it may fly over your head and create more questions for me.

I am taking you at face value here. One or two think you may be a mouse.

[pglancy] 04/12/2016 21:14

Elrico, what was in the header what is the header? And what is SOH?
Thanx

[parob] 04/12/2016 20:29

More on precision medicine.....!

---------------------------------------

The microbiome, nutrition and the future of health



A few excerpts from this article (posted on Friday Dec 2nd)

"There is no such thing as the average patient, and there is no such thing as a one-size-fits-all approach to our health. Fortunately, we’ve reached a point in history when precision medicine – a groundbreaking approach to disease prevention and treatment based on people’s individual differences in environment, genes and lifestyle – is a reality."

"This is only the beginning, though. The potential of precision medicine remains largely untapped. What’s more, we’ve just begun to apply precision medicine’s unique toolset and approach to other vital industries."

"Researchers today are focused on two main areas: The composition and function of the different species of bacteria in our gut, and the optimization of the ideal microbiome that will keep us healthy."

"Recent research has found that probiotics impact different people in different ways, depending on their unique microbiome profile. Live cultures in yogurt may improve a person’s gut health, but they may not. We’re not yet living in a world in which probiotic formulas can be developed to match specific human microbiome profiles. We’re getting there, though. In the next few years, people will regularly have their microbiomes sequenced in order to be able to shop for probiotics that match their specific health needs. Just as people are having their genome sequenced for their clinician to prescribe individualized treatments, the microbiome will be sequenced regularly in order to prescribe individualized diets."

"We’ve barely scratched the surface of the relationships between our food and its microbiome, our own body’s microbiome, and our health. Much more testing and research is needed, but the possibilities are enthralling."

[elrico] 04/12/2016 19:53

If we refer back to the the RNs on 26/10/16 & 29/11/16 we can see the speak is the same, but the key difference is the 29th OPTI gave significant data; see below - 2 key scientific areas; Cholesterol and novel oligosaccharides. It should not be underestimated the importance of these developments. If you remember SOH went in to great detail expanding on how both the IP and strains can cross pollinate, if you will. This used to be in the header someuwin set up, but he has since removed. It is a shame really, because there is a lot of key info in it. I still have the email if anyone wants it. PM me.

Scientific Update 26th October 2016
OptiBiotix has made significant progress in its scientific programmes to develop compounds which modify the human microbiome to prevent, manage and treat disease. The Company believes these developments have the potential to substantially increase the Company's value. These include: -

1. Demonstration in human gut models of the ability of its microbiome modulators to increase the growth rate of specific microbial species in the human microbiome. This has now been demonstrated in multiple species, including OptiBiotix's cholesterol reducing strain (LP-LDL (TM) )
2. Demonstration in human gut models of the ability of its microbiome modulators to enhance a biological effect, such as cholesterol reduction. In the presence of microbiome modulators, OptiBiotix's cholesterol reducing strain (LP-LDL (TM) ) showed a threefold increase in cholesterol reduction.


OptiBiotix believes that this is the ]FIRST TIME that anyone has DEMONSTRATED a TARGET CHANGE in the MICROBIOME leading to an enhanced biological activity and improved health benefit (cholesterol reduction). This creates the opportunity for: -
1. Designer ingredients or supplements which can modify an individual's current microbiome to improve health

2. Combining microbiome modulators with existing products such as probiotics, a market that is expected to be worth more than $46.5bn by 2020 (Markets and Markets)
The results of these studies will be presented at a Microbiome Summit in November 2016 and in a number of publications in mainstream scientific journals at the start of 2017.

Optibiotix expanded on the above on 29th November 2016

-- OptiBiotix has demonstrated the ability of its novel oligosaccharides (carbohydrates that consist of a small number of sugars) to reduce cholesterol in human gut models by >20%. These sugars are heat resistant and stable during processing making them suitable as ingredients in a wide range of products. This finding extends the existing product opportunity offered by OptiBiotix's LP-LDL cholesterol reducing strain from supplements to ingredients, greatly increasing the market opportunity.
END

[parob] 04/12/2016 18:00

Cheers Elrico,

"Global Precision Medicine Market - Growth, Trends and Forecasts (2016 - 2021)"



"The global precision medicine market is expected to reach close to USD 40 billion by the end of 2016, gradually growing at an estimated CAGR of 10.3% by 2021. Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. It is a combination of molecular biology techniques and systems biology. Precision medicine is one of the greatest opportunities for new medical breakthroughs."

[john henry] 04/12/2016 16:03

Starting to look very very interesting. OPTI very much at the forefront of this new age in treatments, medicine etc.

[elrico] 04/12/2016 15:49

Parob - Precision microbiome is one of the items I said was new, as it it offered more details than the previous RNs, where SOH made clear they had, as far as they were aware been the first to develop PM.

[parob] 04/12/2016 11:07

Does anyone recall if precision microbiome medicine has been mentioned in connection with Optibiotix before Tuesday's RNS?

"The potential for precision microbiome medicine. This is an area of growing scientific and commercial interest with growing evidence that the microbiome plays an important role in how the body metabolises pharmaceutical products, influencing their effectiveness and the potential for adverse reactions."

A couple of articles on precision medicine (both from Nov 2016):



"Making the microbiome part of precision medicine"

"In his 2015 State of the Union, President Barack Obama announced the Precision Medicine Initiative, a far-reaching research effort to develop medical treatments tailored for an individual’s unique genetic makeup, environment and lifestyle. Instead of relying on one-size-fits-all solutions designed to help the largest number of statistically average people, such treatments could leverage advances in genetic testing, molecular engineering and big data analysis to target diseases that are often unique to each patient."



"Microbiome’s Role in Precision Medicine"

"Researchers are mapping the microbiome in an effort to better understand disease treatment and prevention. And even to develop personal treatment plans based on an individual’s specific mix of microorganisms and bacteria."

[elrico] 03/12/2016 16:54

Thanks Diamond - Perhaps, but I am often misquoted or misunderstood (I should proof read I guess), so I thought it best to calm Mazz down before we had another situation that got out of hand again.

[misconduct] 03/12/2016 14:18

There is an article in the The Times today that Parkinson's disease may come about when people have the wrong sort of bacteria in their intestines. Scientists in California have found for the first time that giving mice the bacteria from Parkinson's patients made them fall ill with similar symptoms although mice cannot develop Parkinson's. This is another exciting new avenue for the microbiome.

[kipper1960] 02/12/2016 13:43

Mazz, as I said at the time, you made your agenda very clear when you came on the OPTI BB to ramp OXP. (Interesting that you were targeting 3p but sold at 2.5p, or so you say). So, I don't trust your comments and will ignore them, whether on or off topic. Others can do as they choose.

[elrico] 02/12/2016 13:33

Mazz - I don't know where you get the impression I am attacking you? We had a difference of opinion, that is all. I am happy to stand by my view and wait to see what develops. I stated my logic for deal(s) possibly already signed but not disclosed. I did not suggest I was correct, just an hypothesis. On the voting thing...I NEVER vote anyone down, I much prefer to offer a counter opinion, right or wrong. I only vote up when someone has made an effort that is worthy of a vote.

As a footnote; TW agree with my hypothesis - he thinks a lot of investors have not understood the RNs.

Apologies if you think I have been personal, it is not my intention.

[mazzstar] 02/12/2016 13:06

I suspect you accuse me of having a forked tongue because I was right in my interpretation of the latest RNS's? Since my posts from late October onwards I've noticed people marking me down for merely looking at Opti closer than the rose-tinted lot of Elrico and Co. It was clear to me that there would be no deals in November or any signed for that matter. If I deserve a personal attack for stating the obvious then so be it!

[neftanikoff] 02/12/2016 12:29

if you have sold oxp, then that is just as bad, i.e. tipping/ramping a share on here at about the same price you sold at after saying it will hit 3p and then selling shortly afterwards at 2.5, now 1.65. Mazz is not to be trusted. Methinks, he speaks with forked tongue, hopefully no one was foolish to buy in on that poor tip.

[elrico] 02/12/2016 10:55

If you say so Mazz.

[someuwin] 02/12/2016 10:24

The Parkinson's disease / microbiome story now going mainstream...


Parkinson's disease 'may start in gut'

By James Gallagher

Scientists in California say they have transformed understanding of Parkinson's disease.

Their animal experiments, published in the journal Cell, suggest the brain disorder may be caused by bacteria living in the gut.

The findings could eventually lead to new ways of treating the disease, such as drugs to kill gut bugs or probiotics...

[mazzstar] 02/12/2016 10:24

Elrico you're just miffed I pointed out that the RNS on 26/10 confirmed no imminent deals.

[mazzstar] 02/12/2016 10:10

neftan thanks for your concern but I bought OXP at 2p and sold at 2.5p

[kipper1960] 02/12/2016 09:49

i also smell a rat. Or is it a mouse?

[neftanikoff] 02/12/2016 09:23

Mr Gloomy , mazzstar is also a bit miffed as his tip on here , at the time over 2p is now only 1.65p, oh dear, dear dear me.



mazzstar - 25 Oct 2016 - 10:32:32 - 16727 of 17664
3p target for Oxford Pharmascience by the end of the week. I've been waiting for the bounce for weeks.

Oxford Pharmascience (OXP) is worth taking a look at. £21million in cash and the seller appears to be out.

[elrico] 02/12/2016 09:10

Glancy - I did mean to add you gave my ticker a start this AM. I have family with the Glancy name. I though whom had passed and more importantly, who had OPTI squirrelled away without me knowing?

[elrico] 02/12/2016 09:08

No tax is liable if inherited and held in an ISA.

Glancy - Apparently, Mazzstar is accusing me and others of talking the share price of OPTI up (ramp - ramping), a common theme which is sometimes justifiable when no reasonable logic or evidence is attached to the commentary. There quite a few investors that commentate on OPTI and while they (and I include me) may get ahead of ourselves, I believe they are HONEST opinions. I my case I have also been critical, but never been accused of de-ramping OPTI (TALKING THE SHARES DOWN). Mazzstar in all probability is a little miffed with me because I think he is wrong about commercial contracts and the timing of them. We will see soon enough.

Tip - Don't go singing about inheriting x times your yearly salary. We have had our belly full of Walter Mitty types. I am not suggesting you are.

Rather name names; click on the icon top right of the thread, "top posts" for a good idea whom to read. It will give you a short cut rather than wade through page after page.

Sorry for your loss - be happy with your gain.

Good luck

[owenmo] 02/12/2016 08:35

Sorry pglancy I reckon I got that one very wrong; it's inheritance tax thatcAIM Shares side-step, isn't it. As I say I live in different jurisdiction; so just pay no attention!